Member Info for Hurst10

More evidence of the momentum in the gene therapy market.
We will no doubt continue to hear more from Daewoong and Affyxell and their progress in this fast growing market.
:
‘ALBANY, N.Y., April 19, 2022 /PRNewswire/ -- Transparency Market Research: The global gene therapy market was worth around US$ 1.3 Bn in 2020. The global market is likely to rise at a CAGR of 19.8% during the forecast period, from 2021 to 2028. The global gene therapy market is estimated to attain the valuation of US$ 5.3 Bn by 2028. Gene therapy is being promoted as a viable therapeutic option, since it eliminates the need of surgery, medicines, or other potentially harmful treatments. In the global gene therapy market, strategies such as mergers and acquisitions (M&A) are assisting players in boosting research and development in neurological gene therapy products to treat newborns and infants suffering from spinal muscular atrophy (SMA) type 1 (SMA1). Firms in the global gene therapy market are making efforts to obtain clearance from the FDA (Food and Drug Administration) for CAR-T cell therapy products. These products are used for the purpose of treatment of suitable R/R (relapsed or refractory) patients with large B-cell lymphoma. The FDA can grant new gene therapy candidates a classification of the uncommon pediatric disease and also authorization for use in treating metachromatic leukodystrophy.’

Waiting for the other side of the 260,052 sale print.

Because of the unique indications so far from the AVA6000 clinical trial progress, one could not rule out, that the FDA would decide to issue a Breakthrough Therapy Designation,which off course carries huge benefits !
:
The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of products intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must indicate that the product may demonstrate substantial improvement over currently available options on at least one clinically significant endpoint. The benefits of this Breakthrough Therapy Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific liaison to help accelerate review time and potential eligibility for Priority Review if relevant criteria are met.

We do off course have CEO?s post AACR AVA6000 podcast to look forward to and that will obviously not only clarify but also highlight how big AVA6000 could be commercially, in terms of JV?s and revenue going forward

With the current growth rate in gene therapy sector est. to be worth $34 bill by 2030, current valuation of a company like Affyxell could easily reach a figure which would mean AVCT’s 22% stake in AffyXell could be valued at $500 mill, ie. 30% more than the entire market cap of Avacta!
Remember Daewoong provides a ready made ‘route’to the market!

With AffyXell growing in a sector that is really taking off, worth looking at the numbers in the Cell and Gene therapy market.
The market is expected to grow from $4,390.3 million in 2020 to $15,482.3 million in 2025 at a rate of 28.7%. The market is then expected to grow at a CAGR of 17.3% from 2025 and reach $34,317.9 million in 2030.

Meanwhile the M&A in the Oncology sector continues.
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn

Interesting speaker today at AACR :
Carl H. June, MD, is the chair of today’s #AACR22 Plenary Session on Precision Medicine for Immuno-oncology and the Promise for the Future. @PennMedicine @carlhjune.
:
This is very good news and timing for Avacta, Carl H. June, Penn State is a big fan and researcher of Precision Oncology and more importantly Dr. Christina Coughlin worked under his direction at the University of Pennsylvania,while completing her fellowship in Haematology and Oncology at the Children’s hospital in Pennsylvania.

The Conference is getting a lot of coverage and several stocks are announcing trial results etc. which got plenty of coverage and moved the stocks.AVA6000 with Fiona McLaughlin and Neil Bell presenting and speaking of “ AVA6000 significantly decreased tumor volume and increased survival in a dose dependant manner.” And “ The efficacy and tolerability profile of AVA6000 strongly support its clinical development, and a Phase I trial in patients with locally advanced or metastatic selected solid tumours in underway.”
AACR will be all over this novel precision medicine company!

Clearly during June/July post data where the company will be in an incredible position, with a rapid growing Therapeutic division, that quite possible could be listed on Nasdaq at a valuation 6x current share price !

17.00 and Friday !!!
A glass of something nice from the Burgundy awaits.
Suspect perhaps a glass or two at the offices of Avacta could be well deserved.
Have a good week end everybody.
Let us see Monday kick off, post Week End press and discussions.

I meant this one, sorry.
https://www.abstractsonline.com/pp8/#!/10517/presentation/12283

Would that be the latest?

Afternoon everybody, does any have the link to the presentation being made on Monday?
A good week for everybody I hope.
More next week with Conference presentation and Ceo follow up presentation, sure the company will be speaking to several new US Institutions and perhaps a couple of the majors!
A busy week ahead, Monday opening level, to reflect the conference and Ceo speaking again week, should be in 120-5 and as we are well into the second half of second Cohort,with escalated dose.
Soon we will have data from those trials and then the price will begin to reflect a “ proper valuation “, before moving in to new trials.
The stock could easily double from here during spring, no size sellers around!!

Note Afyxell are speaking about acceleration of cell gene therapy, as mention in the presentation a very strong growth market!Sengho Jeon, Chief Executive Officer of Daewoong Pharmaceutical and AffyXell Therapeutics, said:“Through this contract, the capabilities of the three companies can exert a synergistic effect, providing a foundation for speeding up the development of new drugs. In the future, we will further accelerate the development of cell gene therapy to overcome immune diseases and contribute to improving the quality of life of patients with incurable diseases.”

Biocytogen With large presence and office in Boston, US.
This JV will speed things up for Affyxell.

https://biocytogen.com/about-us/our-sites-biocytogen/

Institutions are buying this time and will pay up,to be involved when the company is properly re rated and the value of therapeutic division worth 10x current valuation.

The announcement with China’s Biocytogen mentions a JV named Apicell Therapeutics, I assume it should be Affyxell Therapeutics?

U.K. and US trials running together, sharing data.

Ava6000 phase, now more than half way through with second cohort!!